Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 200-206

  v Laffert, Maximilian ^a   Warth, Arne ^b   Penzel, Roland ^b   Schirmacher, Peter ^b   Jonigk, Danny ^c   Kreipe, Hans ^c   Schildhaus, Hans Ulrich ^d   Merkelbach Bruse, Sabine ^d   Büttner, Reinhard ^d   Reu, Simone ^e   Kerler, Rosi ^e   Jung, Andreas ^e   Kirchner, Thomas ^e   Wölfel, Cornelius ^f   Petersen, Iver ^f   Rodriguez, Regulo ^g   Jochum, Wolfram ^g   Bartsch, Holger ^h   Fisseler Eckhoff, Annette ^h   Berg, Erika ^a   Lenze, Dido ^a   Dietel, Manfred ^a   Hummel, Michael ^a   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^g Kantonsspital St Gallen   (Switzerland)

^h DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Anaplastic lymphoma kinase (ALK) gene rearrangement; Fluorescence in situ hybridization (FISH); Immunohistochemistry (IHC); Non small cell lung cancer (NSCLC); Round robin test

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ANTIBODY SCREENING; ARTICLE; CHROMOSOME BREAKAGE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TISSUE SECTION;

ANAPLASTIC LYMPHOMA KINASE (ALK) GENE REARRANGEMENT; FLUORESCENCE IN SITU HYBRIDIZATION (FISH); IMMUNOHISTOCHEMISTRY (IHC); NON-SMALL CELL LUNG CANCER (NSCLC); ROUND ROBIN TEST;

CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84879888405     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.04.015     Document Type: Article

References (32)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009, 59:225-249.
2. Berghmans T., Paesmans M., Sculier J.P. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 2011, 3:127-138.
3. Berghmans T., Pasleau F., Paesmans M., Bonduelle Y., Cadranel J., Cs Toth I., et al. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2011, 39:9-28.
4. Gaughan E.M., Costa D.B. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011, 3:113-125.
5. Hamburg M.A., Collins F.S. The path to personalized medicine. N Engl J Med 2010, 363:301-304.
6. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
7. Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009, 4:1450-1454.
8. Yoshida A., Tsuta K., Nakamura H., Kohno T., Takahashi F., Asamura H., et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011, 35:1226-1234.
9. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
10. Inamura K., Takeuchi K., Togashi Y., Nomura K., Ninomiya H., Okui M., et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3:13-17.
11. Shinmura K., Kageyama S., Tao H., Bunai T., Suzuki M., Kamo T., et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008, 61:163-169.
12. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
13. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
14. Camidge D.R., Kono S.A., Flacco A., Tan A.C., Doebele R.C., Zhou Q., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010, 16:581-590.
15. Wong D.W., Leung E.L., So K.K., Tam I.Y., Sihoe A.D., Cheng L.C., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.
16. Sasaki T., Rodig S.J., Chirieac L.R., Jänne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
17. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbour EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
18. Shaw A.T., Yeap B.Y., Solomon B.J., Riely G.J., Gainor J., Engelman J.A., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12:1004-1012.
19. Yoshida A., Tsuta K., Nitta H., Hatanaka Y., Asamura H., Sekine I., et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011, 6:1677-1686.
20. McLeer-Florin A., Moro-Sibilot D., Melis A., Salameire D., Lefebvre C., Ceccaldi F., et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012, 7:348-354.
21. Yi E.S., Boland J.M., Maleszewski J.J., Roden A.C., Oliveira A.M., Aubry M.C., et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011, 6:459-465.
22. Thunnissen E., Bubendorf L., Dietel M., Elmberger G., Kerr K., Lopez-Rios F., et al. Consensus statement on testing for EML4-ALK in non-small-cell carcinomas of the lung. Virchows Arch 2012, 461:245-257.
23. Mino-Kenudson M., Chirieac L.R., Law K., Hornick J.L., Lindeman N., Mark E.J., et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010, 16:1561-1571.
24. Murakami Y., Mitsudomi T., Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol 2012, 2:1-9.
25. Just P.A., Cazes A., Audebourg A., Cessot A., Pallier K., Danel C., et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Lung Cancer 2012, 76:309-315.
26. Paik J.H., Choi C.M., Kim H., Jang S.J., Choe G., Kim D.K., et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012, 76:403-409.
27. Kim H., Yoo S.B., Choe J.Y., Paik J.H., Xu X., Nitta H., et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011, 6:1359-1366.
28. Savic S., Bubendorf L. Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 2012, 56:611-621.
29. Perner S., Wagner P.L., Demichelis F., Mehra R., Lafargue C.J., Moss B.J., et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008, 10:298-302.
30. Martelli M.P., Sozzi G., Hernandez L., Pettirossi V., Navarro A., Conte D., et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009, 174:661-670.
31. Camidge D.R., Theodoro M., Maxson D.A., Skokan M., O'Brien T., Lu X., et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive non-small cell lung cancer. Cancer 2012, 118:4486-4494.
32. von Laffert M., Berg E., Lenze D., Lohneis P., Hummel M., Dietel M. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): a glance at "borderline" cases. Poster was presented at the ECCO/ESMO 2012 in Vienna, Poster-ID: 1195P 2012.